Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of
coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the …

Background NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus
2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike …

The current outbreak of the pandemic coronavirus disease 2019 (COVID-19) caused by the
severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) demands its rapid, …

Methods Health care workers who had previously enrolled in a hospital-wide serosurvey study,
3 conducted from July to August 2020 at the University of Maryland Medical Center, were …

Outbreaks of emerging infections present health professionals with the unique challenge of
trying to select appropriate pharmacologic treatments in the clinic with little time available for …

Understanding the molecular basis for immune recognition of SARS-CoV-2 spike glycoprotein
antigenic sites will inform the development of improved therapeutics. We determined the …

COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease
is a virally encoded protein that is essential across a broad spectrum of coronaviruses with …

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants jeopardizes the protective antiviral immunity induced after infection or …

The SARS-CoV-2 virus has infected more than 261 million people and has led to more than
5 million deaths in the past year and a half 1 ( https://www.who.org/ ). Individuals with SARS-…

The COVID-19 pandemic continues to spread throughout the world with an urgent need for
a safe and protective vaccine to effectuate herd protection and control the spread of SARS-…